kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus PDCD1 /PD1 Protein, His tag, 50µg  

Recombinant Cynomolgus PDCD1 /PD1 Protein, His tag, 50µg

Recombinant cynomolgus PDCD1 /PD1 Protein, AA Leu 25 - Gln 167, produced in human HEK293 cells, His tag (MALS verified)

recombinant cynomolgus protein PDCD1, PD1, CD279, SLEB2

More details


Availability: within 7 days

540,00 €

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Recombinant Cynomolgus PD-1, His Tag (PD1-C5223) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # B0LAJ3).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 16.8 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Less than 1.0 EU per μg of the Cynomolgus PDCD1 by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck"
Leddon, Gulati, Haque et al
Clin Cancer Res (2022)
(2) "Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review"
Ito, Kim, Fukuda
Int J Hematol (2022)
(3) "PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect"
Wen, Zeng, Cheng et al
Mol Pharm (2022)
Showing 1-3 of 22604 papers.


(1) "Anti-PD-1 antibodies and compositions"
Authors: G Galler, et al
Journal: US20190144542A1 2019
Application: SPR

The following products could also be interesting for you: